Thyroid function in lung cancer
Abstract
Thyroid function was assessed at the time of initial diagnosis in 204 patients with lung cancer and compared with that of age and sex-matched patients with non-malignant lung disease. Abnormalities in thyroid function were found in 67 patients (33%). The most prevalent abnormality was a low T3 concentration; this was not associated with other clinical or biochemical evidence of hypothyroidism, but the short-term prognosis of these patients was worse than that of matched patients with lung cancer having normal T3 concentrations. Primary hypothyroidism occurred in three patients, low T4 concentrations and free thyroxine index (FTI) with normal thyrotrophin (TSH) concentrations in four patients, and moderately raised TSH with normal thyroid hormone concentrations in six patients; nine patients had a raised FTI with or without raised T4 concentration as the sole abnormality.
Overall, the pattern of thyroid hormone metabolism in lung cancer was a tendency towards reduced T3 concentrations with significantly increased T4/T3 ratios and modestly increased 3,3′,5′-triiodothyronine (rT3) concentrations. The altered T4/T3 ratio was particularly noticeable in patients with anaplastic tumours of small (“oat cell”) and large cell types, but was not apparently related to detectable extrathoracic metastases.
These data suggest that thyroid hormone metabolism is altered in patients with lung cancer by decreased 5′-monodeiodination of T4. The resulting low T3 concentrations and altered T4/T3 ratio may be partly responsible for the reduced ratio of androsterone to aetiocholanolone observed in lung cancer, which is known to be a poor prognostic sign.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (619K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Moossa AR, Evans DA, Brewer AC. Thyroid status and breast cancer. Reappraisal of an old relationship. Ann R Coll Surg Engl. 1973 Sep;53(3):178–188.[PMC free article] [PubMed] [Google Scholar]
- de GENNES, BRICAIRE H, LEPRAT J. [Paraneoplastic endocrine syndromes. II. Hyperthyroidism and various endocrinopathies]. Presse Med. 1962 Oct 27;70:2137–2139. [PubMed] [Google Scholar]
- Challand GS, Ratcliffe WA, Ratcliffe JG. Semi-automated radioimmunoassays for total serum thyroxine and triiodothyronine. Clin Chim Acta. 1975 Apr 2;60(1):25–32. [PubMed] [Google Scholar]
- Ratcliffe WA, Marshall J, Ratcliffe JG. The radioimmunoassay of 3,3',5' - triiodothyronine (reverse T3) in unextracted human serum. Clin Endocrinol (Oxf) 1976 Nov;5(6):631–641. [PubMed] [Google Scholar]
- Hall R, Amos J, Ormston BJ. Radioimmunoassay of human serum thyrotrophin. Br Med J. 1971 Mar 13;1(5749):582–585.[PMC free article] [PubMed] [Google Scholar]
- Britton KE, Quinn V, Ellis SM, Cayley AC, Miralles JM, Brown BL, Ekins RP. Is "T4 toxicosis" a normal biochemical finding in elderly women? Lancet. 1975 Jul 26;2(7926):141–142. [PubMed] [Google Scholar]
- Carter JN, Eastmen CJ, Corcoran JM, Lazarus L. Inhibition of conversion of thyroxine to triiodothyronine in patients with severe chronic illness. Clin Endocrinol (Oxf) 1976 Nov;5(6):587–594. [PubMed] [Google Scholar]
- Amatruda TT, Jr, Upton GV. Paraneoplastic syndromes. Hyperadrenocorticism and ACTH-releasing factor. Ann N Y Acad Sci. 1974;230:168–180. [PubMed] [Google Scholar]
- Burr WA, Black EG, Griffiths RS, Hoffenberg R. Serum triiodothyronine and reverse triiodothyronine concentrations after surgical operation. Lancet. 1975 Dec 27;2(7948):1277–1279. [PubMed] [Google Scholar]
- Rao LG. Discriminant function based on steroid abnormalities in patients with lung cancer. Lancet. 1970 Aug 29;2(7670):441–445. [PubMed] [Google Scholar]